Breaking News

Alibaba Indicated to Start Trading at $84 to $87
Tweet TWEET

CORRECTING and REPLACING Bioanalytical Systems to Release Fourth Quarter & Fiscal 2012 Results Thursday, December 27, 2012;

  CORRECTING and REPLACING Bioanalytical Systems to Release Fourth Quarter &
  Fiscal 2012 Results Thursday, December 27, 2012; Conference Call & Webcast
  Set For 1:00 p.m. EST

CORRECTION...by Bioanalytical Systems, Inc.

Business Wire

WEST LAFAYETTE, Ind. -- December 27, 2012

In headline and first graph of release dated December 18, 2012, conference
call time is changing to 1 PM EST (sted 11 AM EST).

The corrected release reads:

    BIOANALYTICAL SYSTEMS TO RELEASE FOURTH QUARTER & FISCAL 2012 RESULTS
 THURSDAY, DECEMBER 27, 2012; CONFERENCE CALL & WEBCAST SET FOR 1:00 P.M. EST

Bioanalytical Systems, Inc. (NASDAQ:BASI) will release financial results for
the fourth quarter and fiscal year 2012 ended September 30, 2012 at
approximately 8:30 a.m. EST on Thursday, December 27, 2012. BASi has scheduled
a conference call at 1:00 p.m. EST that morning to discuss its results for the
quarter and fiscal 2012. To participate in the call, dial 866.713.8310,
passcode #83355796.

A simultaneous webcast of the conference call may be accessed online from the
Investors tab at www.BASInc.com. The webcast will be available for replay
after 2:00 p.m. EST at this same Internet address. For a telephone replay,
dial 888.286.8010, passcode #41234644 after 2:00 p.m. EST.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research
services and monitoring instruments to the world's leading drug development
companies and medical research organizations. The company focuses on
developing innovative services and products that increase efficiency and
reduce the cost of taking a new drug to market. Visit www.BASinc.com for more
about BASi.

This release may contain forward-looking statements that are subject to risks
and uncertainties including, but not limited to, risks and uncertainties
related to changes in the market and demand for our products and services, the
development, marketing and sales of products and services, changes in
technology, industry standards and regulatory standards, and various market
and operating risks detailed in the company's filings with the Securities and
Exchange Commission.

Contact:

Bioanalytical Systems, Inc.
Jacqueline Lemke, 765-497-5829
Interim President & CEO and CFO
jlemke@BASinc.com
or
Berkman Associates
Neil Berkman, 310-477-3118
info@berkmanassociates.com
 
Press spacebar to pause and continue. Press esc to stop.